IMMUNE PHARMACEUTICALS INC (IMNP)

0.00
0.00 4.76
OTC
Prev Close 0.00
Open 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.24
Volume 159.71K
Exchange OTC
Shares Outstanding 133.70B
Market Cap 708.60K
Div & Yield N.A. (N.A)

Latest News

Immune Pharmaceuticals Inc. Announces Pricing Of $18,000,000 Public Offering Of Convertible Preferred Stock And Warrants

Immune Pharmaceuticals Inc. Announces Pricing Of $18,000,000 Public Offering Of Convertible Preferred Stock And Warrants

Immune Pharmaceuticals Inc. ("Immune") (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the pricing of an...

Immune Pharmaceuticals Announces Presentation At The Liver Meeting 2017

Immune Pharmaceuticals Announces Presentation At The Liver Meeting 2017

Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the results of a study...

(Graphic: Business Wire)

(Graphic: Business Wire)

Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced preliminary results from the first six...

Immune Pharmaceuticals Receives NASDAQ Letter

Immune Pharmaceuticals Receives NASDAQ Letter

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced today that on August 23, 2017, the Company received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC ("Nasdaq") that...

Immune Pharmaceuticals Provides R&D And Business Update And Summary Of Recent Financial Highlights

Immune Pharmaceuticals Provides R&D And Business Update And Summary Of Recent Financial Highlights

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ("Immune" or the "Company") provided the following R&D and business update and summary of recent financial highlights.

Immune Pharmaceuticals Appoints Tony Fiorino, MD, PhD As Chief Medical Officer And Chief Operating Officer

Immune Pharmaceuticals Appoints Tony Fiorino, MD, PhD As Chief Medical Officer And Chief Operating Officer

Immune Pharmaceuticals (NASDAQ:IMNP) (the "Immune" or the "Company") announced today that it has appointed Tony Fiorino, MD, PhD to the joint position of Chief Medical Officer and Chief Operating Officer.

CYTOVIA Inc, IMMUNE Pharma's Oncology Subsidiary, Announces Publication Of Results Showing Anti-Metastatic Properties Of Its Lead Drug Ceplene® And Filing Of A New Worldwide Patent

CYTOVIA Inc, IMMUNE Pharma's Oncology Subsidiary, Announces Publication Of Results Showing Anti-Metastatic Properties Of Its Lead Drug Ceplene® And Filing Of A New Worldwide Patent

Cytovia, the oncology subsidiary of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ("Immune"), a clinical stage biopharmaceutical company, today announced the publication of results showing favorable effects of its lead...

CYTOVIA Inc., IMMUNE Pharma's Oncology Subsidiary, Announces The Publication Of New Results In The British Journal Of Haematology And Filing Of A World-wide Patent Protecting The Use Of Ceplene® In Chronic Myeloid Leukemia (CML)

CYTOVIA Inc., IMMUNE Pharma's Oncology Subsidiary, Announces The Publication Of New Results In The British Journal Of Haematology And Filing Of A World-wide Patent Protecting The Use Of Ceplene® In Chronic Myeloid Leukemia (CML)

Cytovia, the oncology subsidiary of Immune Pharmaceuticals (NASDAQ:IMNP) ("Immune" or the "Company"), a clinical stage biopharmaceutical company, today announced the publication of new results supporting the benefits of its...

Immune Pharmaceuticals, Inc. Issues Letter To Shareholders

Immune Pharmaceuticals, Inc. Issues Letter To Shareholders

Immune Pharmaceuticals Inc. (NASDAQ; IMNP) a clinical stage biopharmaceutical company specializing in the development of novel targeted therapeutic agents in the fields of immuno-inflammation, dermatology and...

Immune Pharmaceuticals Provides Update On Plan To Implement A Spin-off Of Cytovia Into A Separate Publicly Traded Oncology Company

Immune Pharmaceuticals Provides Update On Plan To Implement A Spin-off Of Cytovia Into A Separate Publicly Traded Oncology Company

Immune Pharmaceuticals (NASDAQ: IMNP) ("Immune") today confirmed it is continuing to structure and pursue a spin-off of Cytovia, Inc.

French Election Fires Up Wall Street, Propels Stocks to Best Gains Since Early March

French Election Fires Up Wall Street, Propels Stocks to Best Gains Since Early March

A vote for the status quo lights a fire under European markets, which translates to a great day for Wall Street.

Stocks Follow European Stocks Higher After French Election Brings Relief

Stocks Follow European Stocks Higher After French Election Brings Relief

Stocks enjoy their biggest gains since the beginning of March after centrist Emmanuel Macron wins the first round of the country's presidential elections over far-right Marine Le Pen.

Dow Enjoys 200-Point Surge as Macron Win Provides Comfort to EU Worries

Dow Enjoys 200-Point Surge as Macron Win Provides Comfort to EU Worries

Stocks rocket higher on Monday after centrist Emmanuel Macron wins the first round of the country's presidential elections over far-right Marine Le Pen.

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering big breakout trades.

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look poised to break out and trade higher from current levels.